Data / Drug companies / Larken Laboratories, Inc.
Larken Laboratories, Inc.: 13 products in the FDA NDC directory, labeler code 68047
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Larken Laboratories, Inc. (labeler code 68047) lists 13 products in the FDA National Drug Code Directory, covering 5 finished drugs by generic name. By type: 8 prescription drugs, 5 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on July 30, 2026.
The request: Watch Larken Laboratories, Inc. (FDA labeler code 68047): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 68047
- Products in commercial distribution
- 13
- Packages
- 19
- Finished drugs by generic name
- 5
- Prescription products
- 8
- Over the counter products
- 5
- Controlled substance products
- Schedule III 3
- Flagged as original packager
- 8 of 8 products that carry the flag
- Started marketing in the last 12 months
- 1
- Products with a marketing end date set
- 1
- Earliest marketing start
- September 15, 2003
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 6 | 46.2% |
| Over the counter monograph drugs | 5 | 38.5% |
| Other unapproved drugs | 2 | 15.4% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 8 | 61.5% |
| Over the counter drugs | 5 | 38.5% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Butalbital and acetaminophen | 3 | 9 |
| Chlorpheniramine maleate / pseudoephedrine hcl | 2 | 1 |
| Hyoscyamine sulfate | 2 | 24 |
| Dexamethasone 1.5 mg | 2 | 2 |
| Doxycycline hyclate | 1 | 61 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 7 | 53.8% |
| Liquid | 5 | 38.5% |
| Tablet, orally disintegrating | 1 | 7.7% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| LoHist-D | 68047-159 | Liquid | Over the counter monograph drugs | July 30, 2026 |
| Dexamethasone 1.5 mg | 68047-702 | Tablet | Generic drugs (ANDA) | September 1, 2017 |
| Dexamethasone 1.5 mg | 68047-702 | Tablet | Generic drugs (ANDA) | September 1, 2017 |
| Butalbital and Acetaminophen | 68047-753 | Tablet | Generic drugs (ANDA) | December 4, 2015 |
| Allzital | 68047-752 | Tablet | Generic drugs (ANDA) | December 4, 2015 |
| Butalbital And Acetaminophen | 68047-721 | Tablet | Generic drugs (ANDA) | December 4, 2015 |
| LoHist DM | 68047-129 | Liquid | Over the counter monograph drugs | June 1, 2012 |
| EndaCof DM | 68047-143 | Liquid | Over the counter monograph drugs | March 30, 2012 |
| Oscimin | 68047-253 | Tablet, orally disintegrating | Other unapproved drugs | August 3, 2011 |
| Oscimin | 68047-252 | Tablet | Other unapproved drugs | August 3, 2011 |
| NoHist DM | 68047-186 | Liquid | Over the counter monograph drugs | January 6, 2011 |
| Doxycycline Hyclate | 68047-714 | Tablet | Generic drugs (ANDA) | November 15, 2010 |
| LoHist D | 68047-120 | Liquid | Over the counter monograph drugs | September 15, 2003 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.